î
îŒ
î
AbbVie Inc
ABBVî¹
詳现ãã£ãŒãã衚瀺
220.610USD
+2.060+0.94%
çµå€Â 09/26, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
389.70Bæ䟡ç·é¡
104.67çŽè¿12ã¶æPER
î
Intraday
1m
30m
1h
D
W
M
D
æ¬æ¥
+0.94%
5æ¥é
-0.84%
1ã¶æ
+5.88%
6ã¶æ
+9.59%
幎åæ¥
+24.15%
1幎é
+14.96%
詳现ãã£ãŒãã衚瀺
TradingKey æ ªåŒã¹ã³ã¢î
é貚: USD æŽæ°æå»: 2025-09-26äž»èŠã€ã³ãµã€ã
å瀟ã®è²¡åç¶æ³ã¯æ¯èŒçå®å®ã§ããå瀟ã®æ ªäŸ¡ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸãããŸããæ©é¢æè³å®¶ã«ããèªç¥åºŠã¯éåžžã«é«ãã§ããéå»30æ¥éã§ãè€æ°ã®ã¢ããªã¹ããå瀟ãè²·ããšè©äŸ¡ããŸãããæ ªäŸ¡ã®ããã©ãŒãã³ã¹ã¯å¹³åçã§ããããã¡ã³ãã¡ã³ã¿ã«ãºãšãã¯ãã«ã«ã¯å 調ã§ããæ ªäŸ¡ã¯æ¯æç·ãšæµæç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
æ ªåŒã¹ã³ã¢î°î°
æ¯æç·ãšæµæç·
ããŒã¿ãªã
ã¬ãŒããŒãã£ãŒã
çŸåš
ååå€
ã¢ããªã¹ãç®æšæ ªäŸ¡
31
人ã®ã¢ããªã¹ãäºæ³ã«åºã¥ã
è²·ã
çŸåšã®è©äŸ¡
227.821
ç®æšæ ªäŸ¡
+4.25%
äžæäœå°
å
責äºé
ïŒã¢ããªã¹ãã®ã¬ãŒãã£ã³ã°ããã³ç®æšæ ªäŸ¡ã¯ãæ
å ±æäŸã®ã¿ãç®çãšããŠLSEG Data & AnalyticsãæäŸãããã®ã§ãããæè³å©èšãæ§æãããã®ã§ã¯ãããŸããã
äŒæ¥ãã€ã©ã€ã
匷ã¿ãªã¹ã¯
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It researches and develops, manufactures, commercializes and sells medicines and therapies. Its product portfolio includes immunology, oncology, aesthetics, neuroscience, eye care and Other Specialties. Immunology includes Rheumatology, Dermatology, and Gastroenterology. Oncology includes Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia and Diffuse large B-cell lymphoma. Neuroscience includes Parkinson's disease, Migraine, Movement Disorders, Psychiatric Disorders and Alzheimerâs disease. Eye Care includes Chronic Dry Eye Disease, Glaucoma, Age-Related Retinal Diseases, and Refractive Disorders. Aesthetics includes Botox Cosmetic, The Juvederm Collection of Fillers and others. Its NX-13 for the treatment of ulcerative colitis and Crohn's disease. Its CEL383 for the treatment of inflammatory bowel disease. Its ALIA-1758 for the treatment of patients with Alzheimer's disease.
é«é
åœ
å瀟ã¯é«é
åœéæã§ãããææ°ã®é
åœæ§åã¯263.76%ã§ãã
å®å®é
åœ
å瀟ã¯éå»5幎éã«ãããç¶ç¶çã«é
åœãå®æœããŠãããææ°ã®é
åœæ§åã¯263.76%ã§ãã
å²é«
å瀟ã®ææ°ã®PEã¯104.79ã§ãéå»3幎éã®æ°Žæºãšæ¯èŒããŠé«å€åã«ãããŸãã
æ©é¢æè³å®¶ã®è²·ãå¢ã
ææ°ã®æ©é¢æè³å®¶ã®ä¿ææ ªæ°ã¯1.32Bæ ªã§ãåååææ¯ã§0.78%å¢å ããŠããŸãã
ãã³ã¬ãŒããä¿æ
ã¹ã¿ãŒæè³å®¶ãã³ã¬ãŒãã¯æ¬éæã176.50Mæ ªä¿æããŠããŸãã
ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
財åææšî
EPS
ããŒã¿ãªã
ç·å£²äžé«
ããŒã¿ãªã
äŒæ¥åî
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It researches and develops, manufactures, commercializes and sells medicines and therapies. Its product portfolio includes immunology, oncology, aesthetics, neuroscience, eye care and Other Specialties. Immunology includes Rheumatology, Dermatology, and Gastroenterology. Oncology includes Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia and Diffuse large B-cell lymphoma. Neuroscience includes Parkinson's disease, Migraine, Movement Disorders, Psychiatric Disorders and Alzheimerâs disease. Eye Care includes Chronic Dry Eye Disease, Glaucoma, Age-Related Retinal Diseases, and Refractive Disorders. Aesthetics includes Botox Cosmetic, The Juvederm Collection of Fillers and others. Its NX-13 for the treatment of ulcerative colitis and Crohn's disease. Its CEL383 for the treatment of inflammatory bowel disease. Its ALIA-1758 for the treatment of patients with Alzheimer's disease.
äŒæ¥ã³ãŒãABBV
äŒæ¥åAbbVie Inc
æé«çµå¶è²¬ä»»è
ãCEOãMr. Robert A. Michael, CPA
ãŠã§ããµã€ãhttps://www.abbvie.com/
é¢é£éèåå
+1.36%
+1.10%
+1.19%
+0.31%
+1.21%
-0.79%
+0.66%
+1.00%
+0.66%
+1.04%
+1.01%
+3.27%
+1.59%
+0.83%
+1.26%
0.00%
+1.70%
+1.51%
-0.71%
+3.22%人æ°éæ
109267.92
+9.48Â (+0.01%)
3994.71
-12.62Â (-0.31%)
3760.39
+11.39Â (+0.30%)
64.889
-0.037Â (-0.06%)
1.16956
+0.00302Â (+0.26%)
149.402
-0.386Â (-0.26%)
46.036
+0.868Â (+1.92%)
0.65340
-0.00060Â (-0.09%)
1.33891
+0.00484Â (+0.36%)
542.80
-2.50Â (-0.46%)
